Home › Companies › RELMADA THERAPEUTICS INC. › 2023-2024
At RELMADA THERAPEUTICS INC.'s shareholder meeting held May 24, 2024, in the 2023-2024 proxy season, 70 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 207 separate fund positions. On the most widely held item on that ballot — TO PROVIDE AN ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION. — RELMADA THERAPEUTICS INC.'s filing reports the proposal as not approved, with 43% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: RELMADA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 30, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and RELMADA THERAPEUTICS INC.’s Form 8-K, filed May 30, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 24, 2024: 5 items on RELMADA THERAPEUTICS INC.’s Form 8-K, filed May 30, 2024: 1 approved · 2 not approved · 2 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024
Explore RELMADA THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are RELMADA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 30, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: John Glasspool (Class III, 36 month term) | 7,693,573 | -- | -- | 9,981,548 | 4,311,222 | 44% | Not verified | — |
| Elect Director: Paul Kelly (Class III, 36 month term) | 11,799,277 | -- | -- | 5,875,844 | 4,311,222 | 67% | Not verified | — |
| 2. Ratification of Appointment of Independent Auditors | 19,984,165 | 1,966,620 | 35,558 | -- | -- | 91% | Approved | — |
| 3. Approval of an Amendment to the 2021 Plan | 4,261,878 | 13,407,997 | 5,246 | -- | 4,311,222 | 24% | Not approved | — |
| 4. Advisory Vote to Approve Executive Compensation | 7,529,377 | 10,119,590 | 26,154 | -- | 4,311,222 | 43% | Not approved | — |
Source: RELMADA THERAPEUTICS INC., Form 8-K, filed with the SEC on May 30, 2024 — read the filing on EDGAR.
Each item below shows how the 70 asset managers that disclosed a RELMADA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
44% Plurality election · of votes cast
Description as filed by funds: To elect Class III directors, to serve for a three-year term that expires at the Annual Meeting of Stockholders in 2027, or until his successor is elected and qualified or until his earlier resignation or removal: John Glasspool
RELMADA THERAPEUTICS INC.’s own tally for this item (“Elect Director: John Glasspool (Class III, 36 month term)”): 7,693,573 for, 9,981,548 withheld, per its Form 8-K filed May 30, 2024 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 44% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 835,553 for, 749,029 withheld, 5,107 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 637,153 | 0 | 0 | 0 | For |
| Fidelity | 0 | 0 | 0 | 292,313 | Withhold |
| FRANKLIN STRATEGIC SERIES | 198,400 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 186,477 | Withhold |
| Federated Hermes | 0 | 0 | 0 | 96,010 | Withhold |
| AdvisorShares Trust | 0 | 0 | 0 | 68,053 | Withhold |
| BlackRock | 0 | 0 | 0 | 55,233 | Withhold |
| American Century | 0 | 0 | 0 | 16,397 | Withhold |
| Dimensional | 0 | 0 | 0 | 14,428 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 12,505 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 4,800 | Withhold |
| Jackson National | 0 | 0 | 4,168 | 0 | Abstain |
| Northern Trust | 0 | 0 | 0 | 2,076 | Withhold |
| Equitable | 0 | 0 | 0 | 728 | Withhold |
| John Hancock | 0 | 0 | 519 | 0 | Abstain |
| Allianz | 0 | 0 | 420 | 0 | Abstain |
| Nationwide | 0 | 0 | 0 | 9 | Withhold |
Combines 2 wordings of this item as funds reported it.
67% Majority: yes · of votes cast
Description as filed by funds: To elect Class III directors, to serve for a three-year term that expires at the Annual Meeting of Stockholders in 2027, or until his successor is elected and qualified or until his earlier resignation or removal: Paul Kelly
RELMADA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Paul Kelly (Class III, 36 month term)”): 11,799,277 for, 5,875,844 withheld, per its Form 8-K filed May 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 67% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 1,319,774 for, 269,915 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 637,153 | 0 | 0 | 0 | For |
| Fidelity | 233,303 | 0 | 0 | 59,010 | Mixed |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 198,400 | Withhold |
| BRIDGEWAY FUNDS INC | 186,477 | 0 | 0 | 0 | For |
| Federated Hermes | 96,010 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 68,053 | 0 | 0 | 0 | For |
| BlackRock | 55,233 | 0 | 0 | 0 | For |
| American Century | 16,397 | 0 | 0 | 0 | For |
| Dimensional | 14,428 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 12,505 | Withhold |
| Blackstone Alternative Investment Funds | 4,800 | 0 | 0 | 0 | For |
| Jackson National | 4,168 | 0 | 0 | 0 | For |
| Northern Trust | 2,076 | 0 | 0 | 0 | For |
| Equitable | 728 | 0 | 0 | 0 | For |
| John Hancock | 519 | 0 | 0 | 0 | For |
| Allianz | 420 | 0 | 0 | 0 | For |
| Nationwide | 9 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
24% Not approved · of votes cast
Description as filed by funds: TO APPROVE AN AMENDMENT TO THE RELMADA THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN TO INCREASE THE SHARES OF OUR COMMON STOCK AVAILABLE FOR ISSUANCE THEREUNDER BY 4.5 MILLION SHARES.
RELMADA THERAPEUTICS INC.’s own tally for this item (“3. Approval of an Amendment to the 2021 Plan”): 4,261,878 for, 13,407,997 against — failed, per its Form 8-K filed May 30, 2024 (Item 5.07).
Reported outcome: Not approved, in the filing’s own words: “Stockholders did not approve the proposed amendment to the Company's 2021 Equity Incentive Plan, as amended (the "2021 Plan"), to increase the number of shares of the Company's common stock available for issuance pursuant to awards under the 2021 Plan by 4,500,000 to an aggregate of 12,400,000 (inc…”
Support: 24% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 637,153 | 0 | 0 | 0 | For |
| Fidelity | 0 | 292,313 | 0 | 0 | Against |
| FRANKLIN STRATEGIC SERIES | 0 | 198,400 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 186,477 | 0 | 0 | Against |
| Federated Hermes | 96,010 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 0 | 68,053 | 0 | 0 | Against |
| BlackRock | 55,233 | 0 | 0 | 0 | For |
| American Century | 0 | 16,397 | 0 | 0 | Against |
| Dimensional | 0 | 14,428 | 0 | 0 | Against |
| Charles Schwab | 0 | 12,505 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 4,800 | 0 | 0 | Against |
| Jackson National | 0 | 4,168 | 0 | 0 | Against |
| Northern Trust | 0 | 2,076 | 0 | 0 | Against |
| Equitable | 728 | 0 | 0 | 0 | For |
| John Hancock | 0 | 519 | 0 | 0 | Against |
| Allianz | 0 | 420 | 0 | 0 | Against |
| Nationwide | 0 | 9 | 0 | 0 | Against |
Fund voting reports, all 17 managers: 789,124 for, 800,565 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Palo Alto Investors LP | 0 | 732,400 | 0 | 0 | Against |
| apricus wealth, LLC | 78,862 | 0 | 0 | 0 | For |
Institutional-manager reports, all 2 managers: 78,862 for, 732,400 against.
Combines 3 wordings of this item as funds reported it.
43% Not approved · of votes cast
Description as filed by funds: TO PROVIDE AN ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.
RELMADA THERAPEUTICS INC.’s own tally for this item (“4. Advisory Vote to Approve Executive Compensation”): 7,529,377 for, 10,119,590 against — failed, per its Form 8-K filed May 30, 2024 (Item 5.07).
Reported outcome: Not approved, in the filing’s own words: “Stockholders did not approve, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Company's Proxy Statement for its 2024 Annual Meeting of Stockholders.”
Support: 43% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 637,153 | 0 | 0 | 0 | For |
| Fidelity | 292,313 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 198,400 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 186,477 | 0 | 0 | 0 | For |
| Federated Hermes | 0 | 96,010 | 0 | 0 | Against |
| AdvisorShares Trust | 68,053 | 0 | 0 | 0 | For |
| BlackRock | 55,233 | 0 | 0 | 0 | For |
| American Century | 16,397 | 0 | 0 | 0 | For |
| Dimensional | 0 | 14,428 | 0 | 0 | Against |
| Charles Schwab | 0 | 12,505 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 4,800 | 0 | 0 | 0 | For |
| Jackson National | 0 | 4,168 | 0 | 0 | Against |
| Northern Trust | 2,076 | 0 | 0 | 0 | For |
| Equitable | 728 | 0 | 0 | 0 | For |
| John Hancock | 519 | 0 | 0 | 0 | For |
| Allianz | 0 | 420 | 0 | 0 | Against |
| Nationwide | 9 | 0 | 0 | 0 | For |
Fund voting reports, all 17 managers: 1,263,758 for, 325,931 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 0 | 1,240,034 | 0 | 0 | Against |
| Vestal Point Capital, LP | 1,200,001 | 0 | 0 | 0 | For |
| Palo Alto Investors LP | 0 | 732,400 | 0 | 0 | Against |
| Opaleye Management Inc. | 0 | 731,000 | 0 | 0 | Against |
| FRANKLIN ADVISERS INC | 0 | 600,251 | 0 | 0 | Against |
| ACADIAN ASSET MANAGEMENT LLC | 441,431 | 0 | 0 | 0 | For |
| TIEDEMANN ADVISORS, LLC | 440,674 | 0 | 0 | 0 | For |
| BlackRock | 407,660 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 256,087 | 0 | 0 | 0 | For |
| Two Sigma | 212,274 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 194,777 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 193,678 | 0 | 0 | Against |
| Summit Trail Advisors, LLC | 0 | 178,000 | 0 | 0 | Against |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 125,916 | 0 | 0 | 0 | For |
| Goldman Sachs | 120,422 | 0 | 0 | 0 | For |
| State Street | 111,129 | 0 | 0 | 0 | For |
| Federated Hermes | 0 | 96,010 | 0 | 0 | Against |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 94,048 | 0 | 0 | 0 | For |
| Point72 | 92,660 | 0 | 0 | 0 | For |
| Citadel | 90,318 | 0 | 0 | 0 | For |
| apricus wealth, LLC | 78,862 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 65,720 | 0 | 0 | 0 | For |
| Fidelity | 61,132 | 0 | 0 | 0 | For |
| Northern Trust | 43,980 | 0 | 0 | 0 | For |
| MEYER HANDELMAN CO | 32,545 | 0 | 0 | 0 | For |
Institutional-manager reports, all 61 managers: 4,168,259 for, 3,833,058 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
91% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF MARCUM LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.
RELMADA THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Auditors”): 19,984,165 for, 1,966,620 against — passed, per its Form 8-K filed May 30, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Stockholders approved the ratification of the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 637,153 | 0 | 0 | 0 | For |
| Fidelity | 292,313 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 198,400 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 186,477 | 0 | 0 | 0 | For |
| Federated Hermes | 96,010 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 68,053 | 0 | 0 | 0 | For |
| BlackRock | 55,233 | 0 | 0 | 0 | For |
| American Century | 16,397 | 0 | 0 | 0 | For |
| Dimensional | 14,428 | 0 | 0 | 0 | For |
| Charles Schwab | 12,505 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,800 | 0 | 0 | 0 | For |
| Jackson National | 4,168 | 0 | 0 | 0 | For |
| Northern Trust | 2,076 | 0 | 0 | 0 | For |
| Equitable | 728 | 0 | 0 | 0 | For |
| John Hancock | 519 | 0 | 0 | 0 | For |
| Allianz | 420 | 0 | 0 | 0 | For |
| Nationwide | 9 | 0 | 0 | 0 | For |
Fund voting reports, all 17 managers: 1,589,689 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| apricus wealth, LLC | 78,862 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 78,862 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 30,174,202 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 2.11% |
| 2 | Fidelity | 0.97% |
| 3 | FRANKLIN STRATEGIC SERIES | 0.66% |
| 4 | BRIDGEWAY FUNDS INC | 0.62% |
| 5 | Federated Hermes | 0.32% |
| 6 | AdvisorShares Trust | 0.23% |
| 7 | BlackRock | 0.18% |
| 8 | American Century | 0.05% |
| 9 | Dimensional | 0.05% |
| 10 | Charles Schwab | 0.04% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Deep Track Capital, LP | 4.11% |
| 2 | Vestal Point Capital, LP | 3.98% |
| 3 | Palo Alto Investors LP | 2.43% |
| 4 | Opaleye Management Inc. | 2.42% |
| 5 | FRANKLIN ADVISERS INC | 1.99% |
| 6 | ACADIAN ASSET MANAGEMENT LLC | 1.46% |
| 7 | TIEDEMANN ADVISORS, LLC | 1.46% |
| 8 | BlackRock | 1.35% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 0.85% |
| 10 | Two Sigma | 0.70% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Squadron Capital Management LLC | 6.79% | 13G |
| Franklin Templeton | 2.09% | 13F |
| BlackRock | 1.68% | 13F |
| Vanguard Group | 1.39% | 13F |
| Millennium Management | 1.13% | 13F |
| Geode Capital | 0.85% | 13F |
| Two Sigma | 0.75% | 13F |
| Citadel Advisors | 0.56% | 13F |
| State Street | 0.37% | 13F |
| Northern Trust | 0.27% | 13F |
Percentages above are of 30,174,202 shares outstanding, as reported by RELMADA THERAPEUTICS INC. on its Form 10-Q dated May 3, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from RELMADA THERAPEUTICS INC.’s 10-Q dated May 3, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
RELMADA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page).
proxyvotesnow.com, “RELMADA THERAPEUTICS (RLMD) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/relmada-therapeutics-inc/2024 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.